Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113401 | 1.00 | GPR119 (0.47) | GPR119USP30FPR2CHRNB2CHRNA4 | |
| SCHEMBL652015 | 0.91 | CHRNB2 (0.48) | GPR119USP30FPR2CHRNB2CHRNA4 | |
| SCHEMBL652300 | 0.91 | CHRNB2 (0.48) | GPR119USP30FPR2CHRNB2CHRNA4 | |
| SCHEMBL652471 | 0.88 | GPR119 (0.47) | GPR119USP30FPR2LIPE | |
| SCHEMBL650730 | 0.84 | GPR119 (0.49) | GPR119USP30CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL653926 | 0.84 | GPR119 (0.49) | GPR119USP30CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL2411815 | 0.84 | HRH3 (0.55) | GPR119USP30FPR2LIPE | |
| SCHEMBL2411817 | 0.84 | HRH3 (0.55) | GPR119USP30FPR2LIPE | |
| SCHEMBL2065859 | 0.83 | CHRNB2 (0.48) | GPR119USP30CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL2065863 | 0.83 | CHRNB2 (0.48) | GPR119USP30CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231672-B1 | BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2604611-A1 | N-Biaryl substituted diazabicycloalkane derivatives as agonists of the alpha7 and alpha4beta2 nACh Receptor | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | BRCA1, VHL, AADAC | GPR119 480/4885USP30 3882/4885FPR2 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.